The burden of congenital Chagas disease and implementation of molecular diagnostic tools in Latin America

Albert Picado,1 Israel Cruz,1 Maël Redard-Jacot,1 Alejandro G Schijman,2 Faustino Torrico,3,4 Sergio Sosa-Estani,5,6 Zachary Katz,1 Joseph Mathu Ndung’u1

ABSTRACT

It is estimated that between 8000 and 15,000 Trypanosoma cruzi infected babies are born every year to infected mothers in Chagas disease endemic countries. Currently, poor access to and performance of the current diagnostic algorithm, based on microscopy at birth and serology at 8–12 months after delivery, is one of the barriers to congenital Chagas disease (CCD) control. Detection of parasite DNA using molecular diagnostic tools could be an alternative or complement to current diagnostic methods, but its implementation in endemic regions remains limited. Prompt diagnosis and treatment of CCD cases would have a positive clinical and epidemiological impact. In this paper, we analysed the burden of CCD in Latin America, and the potential use of molecular tests to improve access to early diagnosis and treatment of T. cruzi infected newborns.

INTRODUCTION

In 1998, Russomando et al concluded that ‘the PCR has a clear advantage over conventional techniques for the early detection of congenital transmission of Trypanosoma cruzi infection’. Twenty years later, in endemic countries, the use of molecular tools to diagnose infants infected with T. cruzi, the parasite that causes Chagas disease by congenital transmission from infected mothers, is still limited. The arguments put forward to justify the limited use of molecular tools to diagnose congenital Chagas disease (CCD) in these countries are diverse, including: limited evidence that molecular tests perform better than standard procedures (eg, parasitology at birth and/or serology 8–12 months after birth), lack of standardisation, complexity and cost.

Diagnosing CCD should be a priority in endemic countries, as this has proven clinical and epidemiological benefits. In endemic countries such as Bolivia and Chile, controlling CCD is considered a cost-effective strategy as, in contrast to the disease in adults, the cure rate in infants less than 1 year old is almost 100% and tolerance to treatment is quite good. The cure rate decreases in older paediatric patients undergoing chronic infection. Treated and cured children would not develop cardiac and/or gastrointestinal forms of Chagas disease. Furthermore, if there is no reinfection later in life, treated girls will be significantly less likely to transmit the infection to their infants when they get older. Thus, the best diagnostic strategies for congenital Chagas should therefore be implemented to ensure that cases are identified and treated promptly.

The 63rd World Health Assembly held in Geneva on 21 May 2010 urged governments to ‘establish systems of early detection, in particular for the detection of new infections, congenital infections in newborns’. In endemic countries, the current strategy to diagnose and treat CCD is based on a series of steps which leave much to be desired. First, T. cruzi-infected mothers should be identified by...
serological analysis. Children born to an infected mother should then be tested either by microscopy shortly after birth and/or serology 8–12 months after birth. Children who are positive by microscopy (parasites observed in capillary or umbilical cord blood) and/or serology are considered to be CCD cases and are treated. Serological tests cannot be used to diagnose *T. cruzi* infection in babies soon after they are born as maternal antibodies could cause false positive results. While algorithms for diagnosis of CCD vary from country to country, they adhere to the general multistep process, which has well-reported limitations, in particular the low sensitivity of microscopy and the loss to follow-up at 8–12 months. A number of studies have corroborated the results of Russomando *et al* and have shown that molecular tools performed 1 month after birth, in place of microscopy, outperform the current diagnostic algorithm. However, despite their availability, molecular tests are rarely used to diagnose CCD. To our knowledge, Chile is the only endemic country that routinely uses PCR as part of a national strategy, while Argentina is scaling up its use. In the rest of Latin America, PCR is sometimes mentioned in the guidelines as a potential diagnostic tool but is not included in diagnostic algorithms. In contrast, PCR is part of the diagnostic algorithm for CCD in non-endemic high-income countries, such as Spain and Switzerland.

In this paper, we demonstrate that CCD remains a public health problem in Latin America by estimating the burden of disease, the number of children born to *T. cruzi* infected mothers who should be screened so they can be treated if required and the number of CCD cases missed by the current diagnostic strategy. We have also analysed the limitations and arguments that preclude implementation of molecular tests to diagnose CCD in those countries and suggest ways to overcome them.

**Burdens of CCD and Number of Newborns That Should Be Tested for the Disease**

The WHO estimates that in 2010, there were 8668 new cases of CCD in Latin American countries. These CCD cases represented 22% (8668/38 593) of all new cases of Chagas disease that year. The weight that congenital transmission has in the burden of Chagas disease will continue to increase in significance, as other modes of transmission (eg, vector and blood-transfusion) are being controlled. Transmission of Chagas disease through blood transfusion was interrupted in most Latin American countries (20 out of 21) by 2015 and vectorial transmission has been interrupted in a number of endemic countries and regions. Congenital infection of *T. cruzi* is now the first cause of new cases of Chagas disease in Argentina. The number of CCD cases is used to estimate the burden of congenital transmission; however, there is another key parameter that should be considered when planning and assessing CCD control programmes: the number of babies that should be tested. The number of children born to infected mothers is significantly larger than the number of CCD cases as the transmission rate of *T. cruzi* from mother to child is around 5% (95% CI 4% to 6%) in endemic countries. As it happens with the chronic form of Chagas disease, epidemiological data on CCD are scarce. There are no estimates on the number of children born to *T. cruzi*-infected mothers in endemic countries who should have been tested at birth.

In this paper, we have adapted the model developed by WHO to estimate the burden of Chagas disease in Latin America in 2010 to estimate the number of babies born to *T. cruzi*-infected mothers in the region in 2010. First, we derived demographic data from the WHO report, which was based on 2010 national censuses, whenever these data were available. For those countries without data in the WHO report, population projections were obtained from the United Nations and the Economic Commission for Latin America and the Caribbean. Population tables on women of childbearing age (15–44 years of age) were obtained from the U.S. Census Bureau International Data Base, while annual numbers of births by country were extracted from PAHO/WHO Basic Indicators 2010. We used the *T. cruzi* infection prevalence ranges reported per country to calculate the total population infected and the number of infected women of childbearing age. Finally, we derived birth rates per country—adjusting the rates by a factor of 1.5 due to higher birth rates in rural areas—of infected women of childbearing age, in order to develop a range estimate of the number of babies born to infected mothers.

The number of babies that would need to be tested per year varies from 157 972 to 214 074, depending on the estimate of the prevalence of *T. cruzi* infection (table 1). Argentina, Brazil, Bolivia and Mexico are the countries where most tests should be conducted (figure 1). Taking 5% as the average *T. cruzi* transmission rate from infected mothers to newborns, the annual prevalence of CCD cases in Latin America in 2010 ranged from 7899 to 10 704. These numbers are similar to those estimated by WHO in previous reports: 15 000 in 2006 and 8700 in 2010. Our estimates can be used as a reference but some limitations in the calculations should be considered; for example, the performance of serological tests and the congenital transmission rate vary among countries. Accurate and up-to-date data are needed in endemic countries.

**Sensitivity of the Congenital Chagas Disease Diagnostic Algorithm**

There are no accurate records on the number of infants born to infected mothers that are actually tested in endemic countries. Such data would be useful in estimating the coverage achieved by CCD control programmes and the likely number of cases missed. Sensitivity, defined as the number of Chagas disease cases correctly identified by the diagnostic algorithm, depends on (1) the characteristics of the tests used (eg, sensitivity of microscopy and serology) and (2) the capacity of the
Table 1  Estimated number of infants born to *T. cruzi*-infected mothers and number of congenital Chagas disease cases in 2010 in endemic countries

<table>
<thead>
<tr>
<th>Countries</th>
<th>Population*</th>
<th>Range of <em>T. cruzi</em> infection prevalence†</th>
<th>Range of population infected</th>
<th>Range of women of childbearing age infected</th>
<th>Range of children born from <em>T. cruzi</em> infected women</th>
<th>Range of congenital cases‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>41,343,000</td>
<td>2.20%–4.13%</td>
<td>909,546–1,707,466</td>
<td>200,158–375,751</td>
<td>22,894–42,894</td>
<td>1142–2145</td>
</tr>
<tr>
<td>Belize</td>
<td>315,000</td>
<td>0.30%–0.74%</td>
<td>945–2331</td>
<td>222–547</td>
<td>34–83</td>
<td>2–4</td>
</tr>
<tr>
<td>Bolivia</td>
<td>9,947,000</td>
<td>6.10%–18.00%</td>
<td>606,767–1,790,460</td>
<td>144,198–425,504</td>
<td>23,609–70,551</td>
<td>1195–3528</td>
</tr>
<tr>
<td>Brazil</td>
<td>190,755,799</td>
<td>0.60%–1.02%</td>
<td>1,144,535–1,945,709</td>
<td>284,883–484,301</td>
<td>26,622–45,257</td>
<td>1331–2263</td>
</tr>
<tr>
<td>Chile</td>
<td>17,095,000</td>
<td>0.70%–1.00%</td>
<td>119,665–170,950</td>
<td>27,088–38,697</td>
<td>26,54–37,92</td>
<td>133–190</td>
</tr>
<tr>
<td>Colombia</td>
<td>45,805,000</td>
<td>0.50%–0.96%</td>
<td>229,025–439,728</td>
<td>52,826–101,430</td>
<td>68,64–13,179</td>
<td>343–659</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>4,516,000</td>
<td>0.17%–0.53%</td>
<td>7677–23,935</td>
<td>1887–5882</td>
<td>194–606</td>
<td>10–30</td>
</tr>
<tr>
<td>Ecuador</td>
<td>14,483,499</td>
<td>0.40%–1.74%</td>
<td>57,934–252,013</td>
<td>14,134–61,485</td>
<td>16,64–72,38</td>
<td>83–362</td>
</tr>
<tr>
<td>El Salvador</td>
<td>6,952,000</td>
<td>1.30%–3.70%</td>
<td>90,376–257,224</td>
<td>19,472–55,420</td>
<td>24,36–69,32</td>
<td>122–347</td>
</tr>
<tr>
<td>Guatemala</td>
<td>13,550,000</td>
<td>1.20%–1.98%</td>
<td>162,600–268,290</td>
<td>38,058–62,796</td>
<td>82,75–13,653</td>
<td>414–683</td>
</tr>
<tr>
<td>French Guyana Gayana Surinam</td>
<td>1,501,962</td>
<td>0.80%–1.29%</td>
<td>12,016–19,375</td>
<td>23,86–38,48</td>
<td>67–108</td>
<td>3–5</td>
</tr>
<tr>
<td>Honduras</td>
<td>7,989,000</td>
<td>0.92%–4.20%</td>
<td>73,499–335,538</td>
<td>17,191–78,481</td>
<td>2,799–12,776</td>
<td>140–639</td>
</tr>
<tr>
<td>Mexico</td>
<td>112,468,855</td>
<td>0.78%–1.50%</td>
<td>877,257–1,687,033</td>
<td>21,779–418,768</td>
<td>23,323–44,852</td>
<td>1166–2243</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>5,604,000</td>
<td>0.52%–4.60%</td>
<td>29,141–257,784</td>
<td>75,52–66,804</td>
<td>10,96–96,95</td>
<td>55–485</td>
</tr>
<tr>
<td>Panama</td>
<td>3,557,687</td>
<td>0.01%–0.52%</td>
<td>356–18,500</td>
<td>79–4089</td>
<td>10–545</td>
<td>1–27</td>
</tr>
<tr>
<td>Paraguay</td>
<td>8,688,000</td>
<td>2.13%–5.50%</td>
<td>184,628–476,740</td>
<td>32,938–85,050</td>
<td>49,27–12,722</td>
<td>246–636</td>
</tr>
<tr>
<td>Peru</td>
<td>28,948,000</td>
<td>0.44%–0.69%</td>
<td>127,371–199,741</td>
<td>31,282–49,056</td>
<td>39,66–62,19</td>
<td>198–311</td>
</tr>
<tr>
<td>Uruguay</td>
<td>3,301,000</td>
<td>0.24%–0.80%</td>
<td>79,222–26,408</td>
<td>16,84–66,12</td>
<td>179–595</td>
<td>9–30</td>
</tr>
<tr>
<td>Venezuela</td>
<td>27,223,000</td>
<td>0.71%–1.16%</td>
<td>193,283–315,787</td>
<td>48,532–79,292</td>
<td>63,93–10,445</td>
<td>320–522</td>
</tr>
<tr>
<td>Latin America</td>
<td>544,023,802</td>
<td>1.07%–1.45%</td>
<td>5,821,055–7,888,345</td>
<td>1,404,704–1,903,571</td>
<td>157,972–214,074</td>
<td>7,899–10,704</td>
</tr>
</tbody>
</table>

*Population figures per country accordingly to the U.S. Census Bureau 2010.
†Prevalence range of *T. cruzi* infection as described.22 27 28
‡Estimated range of congenital cases per country as reported by Howard et al.25
*T. cruzi, Trypanosoma cruzi.*
that all pregnant women at risk in Bolivia were screened (319,014 pregnancies estimated in Bolivia in 2009), using a test with a sensitivity of 100%, and the diagnostic algorithm for babies (microscopy and serology) was also 100% sensitive. Had the sensitivity of the algorithm been reduced to 80% (ie, loss to follow-up of babies tested by microscopy but not by serology at 8–12 months), then the total number of CCD cases in Bolivia in 2009 would have been 629 and only 52% (n=329) would have been identified by the NCP.

This case study illustrates the limitations of the current diagnostic tools and the health system in identifying all

health system to screen mothers and newborns when required, including the follow-up of babies 8–12 months after birth.

We used the number of pregnant women screened, their seroprevalence, the number of babies tested and the number of CCD cases identified in Bolivia in 2009, as reported by Alonso-Vega et al.,

to estimate the number of CCD cases missed by the national control programme (NCP) that year. The calculations summarised in Table 2 indicate that 174 patients with CCD would have been missed, as the programme is unable to test all the babies born to T. cruzi-infected mothers. This estimate assumes

Table 2 Number of pregnant women screened, babies tested and CCD cases identified by Bolivia’s national control programme in 2009, and the estimated number of CCD cases missed due to inadequate coverage

<table>
<thead>
<tr>
<th>Variable</th>
<th>Estimates</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pregnant women</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td># of pregnant women screened</td>
<td>112,160</td>
<td>Tables 5–8</td>
</tr>
<tr>
<td># of pregnant women who are also seropositive</td>
<td>24,748</td>
<td>Tables 5–8</td>
</tr>
<tr>
<td>Seroprevalence in pregnant women</td>
<td>22%</td>
<td>Calculated: 24,748/112,160</td>
</tr>
<tr>
<td><strong>Babies born to infected mothers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td># of babies tested</td>
<td>16,185</td>
<td>Tables 5–8</td>
</tr>
<tr>
<td># of babies not tested (assuming one baby per pregnancy)</td>
<td>8,563</td>
<td>Calculated: 24,748–16,185</td>
</tr>
<tr>
<td>% babies tested following the diagnostic algorithm</td>
<td>65%</td>
<td>Calculated: 16,185/24,748</td>
</tr>
<tr>
<td><strong>Congenital Chagas disease (CCD) cases</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td># CCD cases identified</td>
<td>329</td>
<td>Tables 5–8</td>
</tr>
<tr>
<td>Rate of congenital transmission</td>
<td>2%</td>
<td>Calculated: 329/16,185</td>
</tr>
<tr>
<td># of CCD cases missed because babies were not tested</td>
<td>174</td>
<td>Calculated: 2%\times8,563</td>
</tr>
</tbody>
</table>

CCD, congenital Chagas disease.
CCD cases in Bolivia, which may be similar to the situation in other Latin American countries.

**IMPLEMENTATION OF MOLECULAR TOOLS TO TEST FOR CONGENITAL CHAGAS DISEASE**

Development of point-of-care (PoC) tests to diagnose CCD remains a priority and some biomarkers have shown promising results. Until these PoC tests are developed, molecular tools for detection of parasite DNA remain the best alternatives to complement current methods. A number of reasons for the limited implementation of molecular tools in the diagnosis of CCD in endemic countries have been identified. We review the most relevant here.

**Lack of clinical evidence**

PCR has been shown to have a higher sensitivity for parasite detection than other conventional methods such as microscopy, hemoculture or xenodiagnosis. It is also superior to conventional methods in the diagnosis and follow-up of infected newborns. Up to 100% sensitivity has been reported in the detection of *T. cruzi* in neonates within the first 3 months of age, which qualifies PCR for early-stage diagnosis of CCD. However, PCR may not be ideal in cases of CCD without persistent parasitaemia, and as a result, sampling at different time points from birth may be needed. A cohort study in an endemic setting in Bolivia that included PCR in the algorithm for detecting vertical transmission of Chagas disease demonstrated its superiority over serology and microscopy.

**Lack of standardisation**

There are a number of factors affecting the diagnostic performance of PCR that could be a hindrance to standardisation across settings where the use of home-brewed PCR methods is the rule. From the source, volume and timing of clinical sampling to more technical issues such as the use of anticoagulants and/or stabilising agents, the method used to purify DNA, the target DNA sequence, primers and probes design, the chemistry used in the reaction and the platform in which the test is performed. There is evidence that blood sampling at 1 month after birth improves accuracy of molecular diagnosis. And there have been successful examples of validating and harmonising home-brewed or commercial PCR and real-time quantitative PCR methods. Both efforts will hopefully contribute to implement a strategy for a timely and effective diagnosis of CCD.

**Complexity**

Real-time PCR kits for detection of *T. cruzi* are commercially available such as RealCycler CHAG (Progenie, Spain) or TCRUZIDNA.CE (Diagnostics Bioprobes Srl, Italy) but their implementation in low-resource settings is limited due to their cost and the need for cold chain for transport and storage. Thus, the lack of robust, field amenable and ready-to-use PCR formats has limited its use to reference laboratories. A method that could overcome these hurdles is loop-mediated isothermal amplification (LAMP) of DNA. This test is performed at constant temperature (60°C–65°C), enabling amplification with high efficiency, in a short time. A thermocycler is not required but a simpler device that allows for isothermal incubation such as a thermal block. Results are easily visualised using simple detection methods. An advantage of LAMP is that it uses multiple primers targeting different regions of the target DNA, which makes it highly sensitive and specific. Recently, the analytical sensitivity and specificity of a LAMP kit developed by Eiken Chemical Co. (Japan, Loopamp Trypanosoma cruzi Detection Kit) on clinical samples from CCD cases were shown to be similar to those of PCR in Argentina. The simplicity of its format, with reagents dried down in reaction tubes that can be stored at room temperature, enables its use for the diagnosis of CCD in resource-limited settings. Other groups have developed similar LAMP kits to detect *T. cruzi* DNA. Another platform that meets the criteria for implementation of molecular diagnosis at such sites is recombinase polymerase amplification (RPA), which also enables sensitive, specific and rapid amplification of DNA under isothermal conditions. The RPA reaction runs optimally at 37°C–42°C which may present an advantage in terms of energy costs saving. This test can also be produced in dry format and has shown great potential in the diagnosis of infections by protozoan parasites. A prototype RPA test coupled with lateral flow assay for product detection has been used to identify *T. cruzi* infection in dogs, showing similar performance to qPCR.

**Cost and implementation**

While molecular tests may be more expensive than serology or microscopy, their superior diagnostic performance would enable the detection and treatment of a higher number of cases. The high efficacy of treatment of CCD may provide an opportunity to demonstrate that molecular tests are cost-effective, as shown in Chile. Testing for different pathogens using the same platform would reduce costs related to implementation of molecular diagnostics in resource-limited settings. For example, the Loopamp platform by Eiken Chemical Co. has been used to develop LAMP tests for the diagnosis of Chagas disease, leishmaniasis, malaria and tuberculosis, the latter endorsed by WHO. As these diseases are coendemic in various geographic regions, health systems have the possibility of using this platform to test for multiple pathogens.

The barriers to implementing these technologies in resource-limited settings may have less to do with their complexity and more with the fact that they require the engagement and commitment of different stakeholders to align the necessary resources.

**CONCLUSION**

It is 20 years since Russomando et al made their statement about the superiority of PCR over conventional
techniques and yet molecular tools to diagnose CCD in endemic countries have still not been broadly implemented. These tools may not be perfect but undoubtedly have a role to play in CCD control programmes, particularly if we take advantage of recently developed technologies. Improved access to prompt and accurate diagnosis for babies at risk of Trypanosoma cruzi infection should be integrated with other interventions: vector control to avoid reinfestation, treatment of women of childbearing age to prevent congenital transmission, interruption of mother-to-child transmission of HIV and syphilis and screening of congenital disorders in newborns using dried blood spots. Delaying the implementation of more efficient diagnostic algorithms sentences a significant number of children to the risk of developing Chagas disease and transmitting T. cruzi parasites to the next generation.

Recommendations

► Estimate the number of infants born to T. cruzi-infected mothers, and the number of newborns tested in endemic countries per year. These indicators should be used to monitor coverage of CCD control programmes.

► Develop target product profiles to define the technical requirements of point-of-care diagnostic tools (molecular and others) for CCD and support the development and implementation of novel tools to diagnose CCD.

► Establish sample banks of CCD cases and controls to allow a rapid and standardised evaluation of new tools (molecular or others) to diagnose congenital transmission of T. cruzi. These sample banks should be representative of the different endemic areas and should include different sample types (eg, blood and urine).

► Develop and evaluate algorithms to diagnose CCD using molecular tools based on the evidence and experience of control programmes that are currently employing these tools.

Acknowledgements FIND is grateful to its donors, public and private, who have helped bring innovative new diagnostics for diseases of poverty. A full list of FIND’s donors can be found at: https://www.finddx.org/donors/. The Drugs for Neglected Diseases initiative (DNDi) is grateful to its donors, public and private, who have provided funding to DNDi since its inception in 2003. A full list of DNDi’s donors can be found at http://www.dndi.org/donors/donors/.

Contributors AP, IC and MR-J analysed the data. AP drafted the first version of the manuscript. All authors contributed to the final version of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests AP, IC, MR-J, ZK and JMN are employees of the Foundation for Innovative New Diagnostics (FIND). FIND contributed to the development of the Looppamp Trypanosoma cruzi Detection Kit. However, FIND does not have any financial interest in the product. The other authors declare that no competing interests exist.

Provenance and peer review Not commissioned; externally peer reviewed.

Data statement No additional data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


